Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Trends and Finance
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
Fourth-quarter COVID-19 testing revenues of $184 million dropped 75% compared to 2021, but base business revenues, excluding COVID sales, rose 6% year-over-year to $2.15 billion.
February 2, 2023
Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing
Stephen MacMillan, Hologic chairman, president, and CEO, said he believes that the firm is well positioned for long-term growth while COVID testing declines.
February 2, 2023
Roche reports flat diagnostics revenue growth for 2022
For COVID-19 tests, Roche booked 2022 revenues of 4.1 billion Swiss francs, down 13% compared to 4.7 billion Swiss francs in 2021. Revenue growth for its base diagnostics business offset the decline.
February 2, 2023
Genetic Technologies, Qiagen forming strategic alliance
Genetic Technologies said the alliance is expected to support the enhancement of its capabilities through software, hardware, consumable, and other technical solutions.
February 1, 2023
Beckman Coulter, MeMed collaborate to expand adoption of host immune response diagnostic test
MeMed developed its BV test to address the management of patients with acute infection in different clinical settings, including emergency departments, and distinguish between bacterial and viral infections early in the diagnostic process.
January 31, 2023
Jana Care, Roche to develop blood-testing platform for chronic kidney and heart disease
The platform would enable patients to self-administer critical blood tests at home, and allow clinicians to review the test results remotely.
January 31, 2023
Most Popular
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
Roche reports flat diagnostics revenue growth for 2022
French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Duke University developing blood test to detect osteoarthritis progression in the knee
A new blood test may identify osteoarthritis progression in the knee more accurately than other methods, potentially advancing research and new therapies.
January 30, 2023
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
The acquisition was agreed upon in July 2022 as an all-cash transaction valued at approximately $1.53 billion.
February 1, 2023
Roche launches COVID-19 PCR test to detect fast-spreading XBB.1.5 Omicron subvariant
XBB.1.5 is prevalent in the U.S. and is quickly spreading to other countries. It is a subvariant of a SARS-CoV-2 variant called XBB. That lineage is a recombinant of two descendants of the BA.2 lineage, which began spiking early in 2022.
January 26, 2023
Abbott CEO expects high single-digit sales growth excluding COVID-19 revenues in 2023
The firm booked diagnostics segment revenues of $3.31 billion in the fourth quarter, down 26.1% year over year. Nonetheless, its CEO sees some easing of macroenvironment challenges that impacted growth in 2022.
January 25, 2023
VieCure, Labcorp collaborate on clinical workflows, genomic testing
The firms are aiming to assist patient-specific treatment plans by integrating Labcorp’s precision medicine testing with VieCure’s clinical decision-support tool.
January 25, 2023
Quest survey: U.S. adults more comfortable with self-testing, but more familiar with horoscope sign than blood type
The prevalence of COVID-19 brought self-initiated testing to the forefront, Quest noted, with 4 in 5 surveyed claiming they're comfortable using at-home COVID tests.
January 23, 2023
Page 1 of 109
Next Page